Isolated central nervous system relapse in blast crisis of chronic myeloid leukemia: a case report by Hari Priya Raghvan, Caroline Ho Siew Ling, Wee Shiang Yui, Boo Yang Liang, Ehram Jamian, Indhira Subbiah

“…A 46-year-old female with underlying CML in lymphoid blast crisis, previously treated with chemotherapy and tyrosine kinase inhibitors, presented with visual disturbances. …”
Get full text

Determinants of Overall and Progression-Free Survival of Nigerian Patients with Philadelphia-Positive Chronic Myeloid Leukemia by Anthony A. Oyekunle, Rahman A. Bolarinwa, Adesola T. Oyelese, Lateef Salawu, Muheez A. Durosinmi

“…Objective. The tyrosine kinase inhibitors have markedly changed the disease course for patients with Ph+ and/or BCR-ABL1+ chronic myeloid leukemia (CML). …”
Get full text

Modulation of gut microbiota in targeted cancer therapy: insights on the EGFR/VEGF/KRAS pathways by Li Gong, Shixue Yang, Junli Huang, Yongsheng Li

“…Furthermore, modulation of the gut microbiota influences glucose and lipid metabolism, thereby enhancing the response to anti-KRAS agents and addressing diarrhea induced by tyrosine kinase inhibitors. By elucidating the connection between gut microbiota and the EGFR/VEGF/KRAS pathways, this review provides valuable insights for advancing targeted cancer therapy and optimizing treatment outcomes in clinical settings.…”
Get full text

Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab by Meng Wu, Claudia A.M. Fulgenzi, Antonio D’Alessio, Alessio Cortellini, Ciro Celsa, Giulia F. Manfredi, Bernardo Stefanini, Y. Linda Wu, Yi-Hsiang Huang, Anwaar Saeed, Angelo Pirozzi, Tiziana Pressiani, Lorenza Rimassa, Martin Schoenlein, Kornelius Schulze, Johann von Felden, Yehia Mohamed, Ahmed O. Kaseb, Arndt Vogel, Natascha Roehlen, Marianna Silletta, Naoshi Nishida, Masatoshi Kudo, Caterina Vivaldi, Lorenz Balcar, Bernhard Scheiner, Matthias Pinter, Amit G. Singal, Joshua Glover, Susanna Ulahannan, Fredrich Foerster, Arndt Weinmann, Peter R. Galle, Neehar D. Parikh, Wei-Fan Hsu, Alessandro Parisi, Hong Jae Chon, David J. Pinato, Celina Ang

“…In the second line, 155 patients were treated with tyrosine kinase inhibitors (TKIs), 45 with immune checkpoint inhibitor (IO)-based regimens, and 3 had missing data. …”
Get full text

The Mechanisms of Systemic Inflammatory and Immunosuppressive Acute-on-Chronic Liver Failure and Application Prospect of Single-Cell Sequencing by Kai Kou, Xiaodong Sun, Guangyao Tian, Yao Zhi, Zhongqi Fan, Guoyue Lv

“…In this process, the dysfunction of monocyte and macrophage is reflected in the downregulation of HLA-DR and upregulation of MER tyrosine kinase (MERTK), which weakens the antigen presentation function and reduces the secretion of inflammatory cytokines. …”
Get full text

Consensus guidelines for the management of treatment-naïve chronic lymphocytic leukaemia in Singapore (2024) by Yeow Tee Goh, Yvonne Loh, Esther Chan, Yuh Shan Lee, Venkata Sreekanth Sampath, Daryl Tan, Shin Yeu Ong, Chandramouli Nagarajan

“…Due to the superior efficacy of targeted agents (Bruton's tyrosine kinase inhibitors [BTKis] and B-cell lymphoma 2 inhibitors [BCL2is]), sthese are favoured over standard chemotherapy or chemotherapy-immunotherapy, especially for patients with del(17p) or TP53 mutation, and less fit patients. …”
Get full text

Angiogenic Factors and Renal Disease in Pregnancy by Julie S. Rhee, Brett C. Young, Sarosh Rana

“…Prior studies show that there is an angiogenic factor imbalance with elevated levels of antiangiogenic proteins soluble fms-like tyrosine kinase 1 (sFlt1) and soluble endoglin (sEng) and reduced levels of the proangiogenic protein, placental growth factor (PlGF) in women with preeclampsia. …”
Get full text

Proteomic Profiling of Ex Vivo Expanded CD34-Positive Haematopoetic Cells Derived from Umbilical Cord Blood by Heiner Falkenberg, Teja Falk Radke, Gesine Kögler, Kai Stühler

“…In the presented publications, CD34-positive cells were isolated from cord blood and expanded for up to 7 days in media supplemented with stem cell factor (SCF), thrombopoietin (THPO), interleukin 6 (IL-6), and fms-related tyrosine kinase 3 ligand (FLT3lg). At days 3 and 7, expanded cells were harvested and analyzed by flow cytometry and quantitative proteomics. 2970 proteins were identified, whereof proteomic analysis showed 440 proteins significantly changed in abundance during ex vivo expansion. …”
Get full text

Interleukin-22 Plays a Protective Role by Regulating the JAK2-STAT3 Pathway to Improve Inflammation, Oxidative Stress, and Neuronal Apoptosis following Cerebral Ischemia-Reperfusio... by Yongfei Dong, Chengyun Hu, Chunxia Huang, Jie Gao, Wanxiang Niu, Di Wang, Yang Wang, Chaoshi Niu

“…Moreover, IL-22 treatment significantly increased Janus tyrosine kinase (JAK) 2 and signal transducer and activator of transcription (STAT) 3 phosphorylation levels in mice and PC12 cells, and STAT3 knockdown abolished the IL-22-mediated neuroprotective function. …”
Get full text

An Unsuspected Finding of t(9;22): A Rare Case of Philadelphia Chromosome-Positive B-Lymphoblastic Lymphoma by Prajwal Boddu, C. Cameron Yin, Rashmi Kanagal-Shamanna, Guillin Tang, Beenu Thakral, Tapan Kadia, Marina Konopleva, Elias Jabbour, Nitin Jain

“…Had it not been for this fortuitous discovery, the patient would not have been treated with tyrosine kinase inhibitors. We emphasize that FISH and PCR testing for BCR-ABL1 rearrangement are integral to arriving at an accurate diagnosis and should be routinely tested on B-LBL biopsy specimens.…”
Get full text

Molecular cloning of EZH2 oncogene in chronic myeloid leukemia and therapeutic prospects by Juliana Costa Gaspar, Lucas Santos de Santana, Camila Menezes Freire de Souza, Marcos Montani Caseiro, Rosane Rezende de Souza Giuliani, Cleide Barbieri de Souza

“…Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia, caused in 95 % of the cases by a cytogenetic abnormality characterized by the reciprocal translocation between chromosomes 9 and 22 t(9; 22) (q34; q11), resulting in Philadelphia chromosome (Ph).Considering that CML cure is only possible with a successful bone marrow transplantation and that there are resistance cases to the tyrosine kinase inhibitor Imatinib Mesylate, prescribed in first line drug treatment; it is important to know in detail the genes and proteins that are possibly altered in CML, favoring effective therapeutic strategies, optimized diagnosis and minimal residual disease detection. …”
Get full text

IGF-1R Inhibition Suppresses Cell Proliferation and Increases Radiosensitivity in Nasopharyngeal Carcinoma Cells by Zhe Wang, Guangyan Liu, Jiwei Mao, Min Xie, Ming Zhao, Xuefen Guo, Shanshan Liang, Heming Li, Xuefeng Li, Ruoyu Wang

“…Linsitinib is an oral small molecule and is a tyrosine kinase inhibitor (TKI) of IGF-1R, which has been known for antitumor effects used widely. …”
Get full text

Tumor Reduction with Pazopanib in a Patient with Recurrent Lumbar Chordoma by Maurício Fernando Silva Almeida Ribeiro, Micelange Carvalho de Sousa, Samir Abdallah Hanna, Marcos Vinicius Calfat Maldaun, Ceci Obara Kurimori, Luiz Guilherme Cernaglia Aureliano de Lima, Romulo Loss Mattedi, Rodrigo Ramella Munhoz

“…A large proportion of these tumors express stem-cell factor receptor (c-KIT) and platelet-derived growth factor receptors (PDGFRs), providing a rationale for the use of tyrosine-kinase inhibitors (TKIs). Case report. A 27-year-old male presented with recurrent chordoma of the lumbar spine 4 years after initial diagnosis. …”
Get full text

Molecular Mechanisms and Therapeutic Prospects of Immunotherapy and Targeted Therapy in Primary Central Nervous System Lymphoma by Lin Zhong MM, Anqing Lu MB, Xiyue Lu MM, Xiaoyin Liu MD, Lujia Cao MM, Shihong Zhu MM, SiJun Diao MM, Xu Cheng MM, Hongwei Wu MB, Jing Chen MD

“…With a deeper understanding of the pathophysiology of PCNSL, various therapies, including CD20 monoclonal antibodies, Bruton's tyrosine kinase (BTK) inhibitors, immunomodulatory drugs, immune checkpoint inhibitors, phosphoinositide 3-kinase (PI3 K)/mammalian target of rapamycin(mTOR) inhibitors, and chimeric antigen receptor (CAR) -T cells are increasingly being applied and have demonstrated considerable efficacy. …”
Get full text

Optimal Molecular Methods in Detecting p190BCR-ABL Fusion Variants in Hematologic Malignancies: A Case Report and Review of the Literature by Rebecca J. Sonu, Brian A. Jonas, Denis M. Dwyre, Jeffrey P. Gregg, Hooman H. Rashidi

“…Patients with BCR-ABL1 positive hematologic malignancies and Philadelphia-like B-lymphoblastic leukemia (B-ALL) are potential candidates for targeted therapy with tyrosine kinase inhibitors (TKI). Before TKIs, patients with B-ALL had a much worse prognosis and current treatments with targeted TKI therapy have improved outcomes. …”
Get full text

Enhancing immunotherapy efficacy in colorectal cancer: targeting the FGR-AKT-SP1-DKK1 axis with DCC-2036 (Rebastinib) by Xiguang Chen, Qiting Zeng, Liyang Yin, Bingru Yan, Chen Wu, Jianbo Feng, Ying Wu, Jun He, Wenjun Ding, Jing Zhong, Yingying Shen, Xuyu Zu

“…Abstract This research demonstrates that DCC-2036 (Rebastinib), a potent third-generation tyrosine kinase inhibitor (TKI), effectively suppresses tumor growth in colorectal cancer (CRC) models with functional immune systems. …”
Get full text

Myeloid Neoplasms with t(5;12) and ETV6-ACSL6 Gene Fusion, Potential Mimickers of Myeloid Neoplasm with PDGFRB Rearrangement: Case Report with Imatinib Therapy and Review of the Li... by Javier De Luca-Johnson, Jose I. Ruades Ninfea, Lauren Pearson, Joanna Conant, Ronald Bryant, Neil A. Zakai, Mary E. Tang

“…In particular, while tyrosine kinase inhibitor therapy is effective in patients with PDGFRB rearrangement, there is little information on imatinib efficacy in patients with ETV6-ACSL6 gene fusion. …”
Get full text

Aberrant heterochromatin silences immune response genes in chronic lymphocytic leukemia by Olivia M. Depies, Qianqian Guo, Yuan Gao, Sutapa Sinha, Zhenqing Ye, Weiguo Han, Kari G. Rabe, Mingma S. Hoel, Heather C. Darby, Chuanhe Yu, Esteban Braggio, Sameer A. Parikh, Susan L. Slager, Neil E. Kay, Zhiquan Wang

“…Finally, when treated with the Bruton tyrosine kinase inhibitor ibrutinib, these silenced enhancers are relatively stable during therapy compared with the CLL-gained enhancers. …”
Get full text

Esophageal Gastrointestinal Stromal Tumor with Rare Intracranial Metastasis by José Carvalho, Margarida Teixeira, Francisco Teixeira Silva, Alexandra Esteves, Carlos Ribeiro, Diana Guerra

“…Our patient lived for 13 years with excellent disease control with imatinib, but the fact that it does not cross the blood-brain barrier makes it not useful in preventing or treating brain lesions. New tyrosine kinase inhibitors that may cross the blood-brain barrier could be the answer to these cases.…”
Get full text

Determination of Crizotinib in Mouse Tissues by LC-MS/MS and Its Application to a Tissue Distribution Study by Fang Zhao, Yuan Wei, Yiming Yan, Han Liu, Sitong Zhou, Bo Ren, Ruijuan Liu

“…Toxicity induced by crizotinib, a small-molecule tyrosine kinase inhibitor, is a significant clinical issue during treatment. …”
Get full text